Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of Limertinib in Healthy Subjects
NCT04360915Phase 1Completed
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of limertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Dec 2019; status: completed.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04360915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360915.